A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation (LIBREXIA-AF)
J
John Strobel, MD
Primary Investigator
Overview
The purpose of this study is to evaluate if milvexian is at least as effective as apixabanducing the risk of the composite stroke and non- central nervous system (CNS) systemicbolism.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Atrial Fibrillation
-
Age: 18 Years
-
Gender: All
Inclusion Criteria:
- Minimum age of 18 years
- Medically stable and appropriate for chronic antithrombotic treatment
- Atrial fibrillation eligible to receive anticoagulation
- Participant must satisfy one or both of the following categories of risk factors (a orb): a) one or more of the following risk factors: i) age greater than or equal to 75years, ii) history of a clinical symptomatic stroke. b) two or more of the followingk factors: i) age between 65 and 74 years, ii) hypertension, iii) diabetesus, iv) atherosclerotic vascular disease, v) heart failure
Exclusion Criteria:
- Hemodynamically significant valve disease or those with valve disease that willy require surgical valve replacement during the study
- Any condition other than AF that requires chronic anticoagulation
Updated on
04 May 2024.
Study ID: CR109220
Please visit our main page to search for other studies you may be interested in.
If you need help finding a study or have any questions, please contact us at inhealth@iu.edu
